Ocumetics Begins Patient Recruitment for Group Two Clinical Study of Next-Generation Intraocular Lens

Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announced that its clinical facility in Mexico City has started recruiting patients for the second group of its ongoing human clinical study of the Ocumetics Lens, a next-generation accommodating intraocular lens. The Group Two study will evaluate the lens for safety as well as near and distance vision performance, moving beyond the safety-only focus of Group One.

The company stated that the Mexico City facility, which successfully conducted Group One surgeries in fall 2025, has begun identifying eligible patients, with surgeries targeted for fall 2026. Group Two patients will receive the latest-generation Ocumetics Lens, which incorporates design advancements and will be implanted using an enhanced delivery system.

Dean Burns, President and CEO of Ocumetics, expressed excitement about advancing to the larger Group Two study, calling it another important milestone in the clinical development of the lens. He noted that recruiting will be completed soon and surgical dates will be scheduled shortly thereafter.

The announcement comes as Group One patients are reaching their 12-month follow-up visits, which will provide longer-term clinical data. The company reported that Group One outcomes met and exceeded expectations regarding safety, performance, and handling of the lens.

The Ocumetics Lens is designed to fit within the natural lens compartment of the eye and use the eye's natural muscle activity to shift focus from distance to near, potentially eliminating the need for corrective lenses. The technology aims to provide clear vision at all distances without glasses or contact lenses.

This clinical progress is significant for the ophthalmic industry, as it moves toward a potential breakthrough in vision correction. The initiation of Group Two marks a step forward in validating the lens's performance and safety in a broader patient population. Positive results could position Ocumetics to disrupt the market for intraocular lenses, offering an alternative to traditional monofocal or multifocal lenses.

For more information, visit the company's website or its profile on NewMediaWire.